NTLA

Intellia Therapeutics Inc

11.34

Oct 22 • 8:44 AM ET -0.31 (-2.66%)

Healthcare Biotechnology USA Small NASD

Peers: BEAM CRSP EDIT PRME ALNY IONS PHVS BBIO SCTX BCRX

| Held by: ARKE ARKK XBI VTI IWM VB ARKG VBK VXF IWN

Index	RUT
Market Cap	1.59B
Enterprise Value	1.22B
Income	-399.98M
Sales	59.51M
Book/sh	5.20
Cash/sh	3.12
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	377
IPO	May 06, 2016

P/E	-
Forward P/E	-
PEG	-
P/S	26.70
P/B	2.18
P/C	3.63
P/FCF	-
EV/EBITDA	-
EV/Sales	20.58
Quick Ratio	6.65
Current Ratio	6.65
Debt/Eq	0.10
LT Debt/Eq	0.07
Option/Short	Yes / Yes

EPS (ttm)	-3.36
EPS next Y	-2.63
EPS next Q	-0.80
EPS this Y	16.05%
EPS next Y	17.90%
EPS next 5Y	24.19%
EPS past 3/5Y	14.82% -9.70%
Sales past 3/5Y	9.09% 3.13%
EPS Y/Y TTM	28.42%
Sales Y/Y TTM	12.58%
EPS Q/Q	18.15%
Sales Q/Q	-46.23%
Earnings	Aug 06 BMO
EPS/Sales Surpr.	-0.09% -40.99%

Insider Own	4.41%
Insider Trans	-0.64%
Inst Own	99.66%
Inst Trans	30.34%
ROA	-45.55%
ROE	-55.44%
ROIC	-51.43%
Gross Margin	74.37%
Oper. Margin	-711.66%
Profit Margin	-672.16%
SMA20	-5.20%
SMA50	-7.23%
SMA200	-13.06%
Trades

Shs Outstand	140.02M
Shs Float	133.94M
Short Float	33.68%
Short Ratio	10.45
Short Interest	45.11M
52W High	26.90 -57.84%
52W Low	7.95 42.64%
Volatility	5.51% 6.26%
ATR (14)	0.69
RSI (14)	42.70
Beta	1.85
Rel Volume	0.06
Avg Volume	4.32M
Volume	13,986

Perf Week	0.00%
Perf Month	-8.03%
Perf Quarter	5.68%
Perf Half Y	-28.54%
Perf YTD	26.14%
Perf Year	-53.86%
Perf 3Y	-57.43%
Perf 5Y	-91.38%
Perf 10Y	-17.71%
Recom	2.40
Target Price	22.88
Prev Close	11.65
Price	11.34
Change %	-2.66%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-06-26	Initiated	Barclays	Underweight	$8
Jul-16-26	Downgrade	Wolfe Research	Peer Perform → Underperform	$9
Mar-02-26	Upgrade	William Blair	Mkt Perform → Outperform
Nov-12-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Nov-11-25	Downgrade	Evercore ISI	Outperform → In-line	$8
Nov-07-25	Downgrade	JP Morgan	Neutral → Underweight	$5
Oct-28-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$14
Oct-28-25	Downgrade	Bernstein	Outperform → Mkt Perform
Oct-27-25	Downgrade	William Blair	Outperform → Mkt Perform
Oct-27-25	Downgrade	Guggenheim	Buy → Neutral
Oct-06-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform	$33
Apr-21-25	Upgrade	Wolfe Research	Peer Perform → Outperform	$21
Mar-05-25	Initiated	H.C. Wainwright	Buy	$30
Feb-28-25	Downgrade	JP Morgan	Overweight → Neutral	$45 → $13
Feb-28-25	Downgrade	Goldman	Neutral → Sell	$9
Jan-27-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$56 → $11
Feb-23-24	Downgrade	Goldman	Buy → Neutral	$136 → $32
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Apr-13-23	Initiated	Canaccord Genuity	Buy	$66
Mar-21-23	Initiated	Bernstein	Outperform	$54

Show Previous Ratings

Oct-13-26 07:30AM	Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire) -5.33%
Oct-06-26 09:50AM	Nike downgraded, Home Depot initiated: Wall Street's top analyst calls (The Fly)
08:16AM	Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies Unloads $18M Worth Of TWST Shares (Stocktwits)
Oct-02-26 04:01PM	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-24-26 08:46AM	Anthropic AI Discovery Gene-Editing Stocks Falling (GuruFocus.com)
05:49PM	Loading…
Sep-23-26 05:49PM	CRSP, NTLA, BEAM, PRME, EDIT Shares Slip Did Claude Just Spook Gene-Editing Stocks? (Stocktwits)
Sep-08-26 10:08AM	Cathie Woods Biotech Bet Intellia Secured An FDA Priority Review For Rare Genetic Disorder Therapy Retail Sees Upside In NTLAs Platform (Stocktwits)
08:48AM	Intellia Therapeutics Shares Rise as FDA Grants Priority Review to Lonvo-z (InvestorsHub)
08:00AM	Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE) (GlobeNewswire)
Sep-04-26 04:05PM	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:50AM	Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million (GlobeNewswire)
08:00AM	Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference (GlobeNewswire)
Aug-12-26 03:30PM	These Are the Stocks Wall Street Is Betting Against the Most (GuruFocus.com)
Aug-07-26 04:01PM	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.23%
08:30AM	Intellia Therapeutics, Inc. Q2 2026 Earnings Call Summary (Moby)
06:02AM	Loading…
06:02AM	Significant demand for Revolution drug; Intellia pinpoints liver toxicity culprit (BioPharma Dive)
Aug-06-26 03:03PM	Intellia Therapeutics Inc (NTLA) (Q2 2026) Earnings Call Highlights: Advancing LONVOSI Toward ... (GuruFocus.com)
07:00AM	Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
Jul-30-26 08:00AM	Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
Jul-06-26 04:05PM	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-15-26 04:10AM	Why Is NTLA Stock Jumping 5% Premarket Today? (Stocktwits) +23.20%
Jun-13-26 07:30AM	Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (GlobeNewswire)
Jun-05-26 04:05PM	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.20%
Jun-01-26 07:30AM	Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026 (GlobeNewswire)
May-11-26 07:30AM	Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
May-05-26 07:30AM	Intellia Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-04-26 01:21PM	Cathie Wood Dumps $72 Million of AMD, Doubles Down on Alphabet and Meta (GuruFocus.com)
May-01-26 04:01PM	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-30-26 08:39AM	Cathie Wood Buys Tumbling Robinhood Stock, ARK Adds $30 Mil Of This Stock (Investor's Business Daily) +8.32%
Apr-29-26 09:50AM	Cathie Wood Loads Up $14 Million on Alphabet Just Before Earnings (GuruFocus.com) -5.72%
07:00AM	Loading…
07:00AM	Intellia Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
Apr-27-26 04:01PM	Intellia Announces Proposed Public Offering of Common Stock (GlobeNewswire)
02:43PM	Intellia Stock Jumps 25%. A Key Trial Is Driving the Rally (GuruFocus.com)
11:20AM	Intellia Therapeutics Shares Slip Despite Strong Phase 3 Data (InvestorsHub)
11:07AM	This Biotech Just Lodged A First In Gene Editing; Why Analysts Are Split (Investor's Business Daily)
11:02AM	Intellia seeks FDA approval for in vivo CRISPR therapy (Quartz)
09:39AM	Intellia Stock Up on Gene-Editing Drug Success (The Wall Street Journal)
07:00AM	Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing (GlobeNewswire)
07:00AM	Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema (GlobeNewswire)
04:48AM	Intellia CRISPR drug succeeds in late-stage study against rare swelling disorder (BioPharma Dive)
Apr-24-26 04:05PM	Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026 (GlobeNewswire) -14.11%
Apr-03-26 04:05PM	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-09-26 09:00AM	Take the Zacks Approach to Beat the Markets: Starbucks, Amgen, Allogene in Focus (Zacks)
Mar-06-26 04:01PM	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-04-26 09:39AM	Roblox initiated, Target upgraded: Wall Street's top analyst calls (The Fly)
Mar-03-26 07:49PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) -11.88%
09:00AM	Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone (PR Newswire)
07:30AM	Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026 (GlobeNewswire)
Mar-02-26 06:44PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) +12.05%
10:05AM	Intellia Therapeutics Stock Gains - FDA Lifts Clinical Hold On Pivotal Trial (Benzinga)
07:30AM	Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM (GlobeNewswire)
Feb-28-26 10:07AM	Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory (Insider Monkey)
02:21AM	Intellia Therapeutics (NTLA) Announces Fiscal Q4 and Full Year 2025 Financial Results (Insider Monkey)
Feb-27-26 11:14AM	Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline (Zacks)
12:07AM	Intellia Therapeutics Q4 Earnings Call Highlights (MarketBeat)
Feb-26-26 04:34PM	Intellia Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby) +6.41%
04:14PM	Intellia Therapeutics Inc (NTLA) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
12:15PM	Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates (GlobeNewswire)
Feb-24-26 08:00AM	Intellia Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-23-26 10:35AM	ImmunityBio (IBRX) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
09:07AM	What's in Store for These 5 Medical Companies This Earnings Season? (Zacks)
08:04AM	Take the Zacks Approach to Beat the Markets: Intellia, Colgate-Palmolive, Getty in Focus (Zacks)
Feb-19-26 07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates (GlobeNewswire)
Feb-17-26 04:58PM	Cathie Wood Buys COIN, HOOD (GuruFocus.com)
Feb-15-26 08:41AM	H.C. Wainwright Boosts Intellia (NTLA) Price Target After MAGNITUDE-2 Hold Lifted (Insider Monkey)
Feb-09-26 08:02AM	Take the Zacks Approach to Beat the Markets: Hershey's, Fastenal, Kennametal in Focus (Zacks)
Feb-06-26 07:30AM	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.73%
Feb-04-26 07:27PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) -5.29% -10.28%
Feb-02-26 09:37AM	Baird Updates Intellia Therapeutics, Inc. (NTLA)'s Financial Model Following Nex-Z Clinical Hold Removal (Insider Monkey)
08:25AM	Twist Bioscience (TWST) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
Jan-28-26 09:45AM	NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold (Zacks) -6.81%
07:35AM	Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains? (Zacks)
06:33AM	Intellia Therapeutics to resume dosing of gene therapy in Phase III trial (Clinical Trials Arena)
Jan-27-26 04:04PM	The Gene-Editing News That Sent Beleaguered Intellia Therapeutics Stock Up (Investor's Business Daily) +6.31%
01:03PM	Intellia Moves Forward As FDA Removes Trial Hold For Rare Disorder (Benzinga)
08:31AM	Intellia gets FDA nod to resume gene therapy trial after safety pause (Reuters)
08:00AM	Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN (GlobeNewswire)
06:59AM	FDA lifts hold on an Intellia CRISPR drug trial (BioPharma Dive)
Jan-22-26 08:47PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) +13.33% -7.99%
Jan-19-26 01:27PM	Cathie Wood Buys AI Chips, Sells Tesla (GuruFocus.com)
Jan-15-26 10:56AM	JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death (Clinical Trials Arena)
Jan-14-26 09:30AM	Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 200-Day Moving Average (Zacks)
Jan-07-26 07:30AM	Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-05-26 12:23PM	ARK Invest Boosts Gene-Editing Bets While Cutting Consumer Tech Exposure (GuruFocus.com)
10:58AM	Intellia Stock Declines Around 55% in 3 Months: Here's Why (Zacks)
Jan-02-26 04:01PM	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-31-25 01:33PM	Cathie Wood shells out $1.3 million on biotech stock (TheStreet)
09:32AM	Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry? (Zacks)
06:26AM	Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab (GuruFocus.com)
Dec-30-25 07:35AM	What Makes Intellia Therapeutics (NTLA) an Interesting Investment? (Insider Monkey)
Dec-29-25 09:50AM	2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street (Motley Fool)
Dec-05-25 04:01PM	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-04-25 01:41PM	Intellia Therapeutics, Inc. (NTLA): A Bear Case Theory (Insider Monkey) +7.51%
Dec-02-25 08:00AM	How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint (Investor's Business Daily)
Nov-28-25 09:59AM	Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry? (Zacks) +5.52%
Nov-27-25 08:15AM	BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential? (Zacks)
Nov-25-25 08:39AM	Intellia Therapeutics (NTLA) Downgraded After Safety Concerns and Regulatory Delays Slow Gene-Editing Progress (Insider Monkey)
Nov-21-25 10:19AM	NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks)
Nov-18-25 08:48AM	Top 3 Genomics Stocks to Consider for Your Portfolio (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dube Michael P	VP, Chief Accounting Officer	Oct 02 '26	Sale	12.43	1,864	23,170	65,022	Oct 06 04:05 PM
ELIANA CLARK	Officer	Oct 05 '26	Proposed Sale	12.75	57,750	736,312		Oct 05 04:45 PM
LEONARD JOHN M	President and CEO	Aug 20 '26	Sale	12.60	19,890	250,614	1,149,849	Aug 24 04:05 PM
LEONARD JOHN M	President and CEO	Aug 21 '26	Sale	13.00	2,785	36,205	1,147,064	Aug 24 04:05 PM
LEONARD JOHN M	Officer	Aug 20 '26	Proposed Sale	12.95	22,675	293,641		Aug 20 04:03 PM
Dulac Edward J III	EVP, Chief Financial Officer	Jul 22 '26	Sale	11.25	8,111	91,249	148,175	Jul 24 05:26 PM
Dube Michael P	VP, Chief Accounting Officer	Jul 01 '26	Sale	16.78	2,641	44,316	66,886	Jul 06 05:02 PM
Dulac Edward J III	EVP, Chief Financial Officer	Jul 02 '26	Sale	18.00	4,677	84,186	156,286	Jul 06 05:01 PM
EDWARD DULAC	Officer	Jul 02 '26	Proposed Sale	17.24	4,677	80,631		Jul 02 04:32 PM
BASTA JAMES	EVP, General Counsel	Mar 02 '26	Sale	13.78	1,211	16,688	156,794	Mar 03 04:18 PM
Clark Eliana	EVP, Chief Technical Officer	Mar 02 '26	Sale	13.78	607	8,364	93,864	Mar 03 04:16 PM
LEONARD JOHN M	President and CEO	Jan 05 '26	Sale	9.21	34,146	314,485	1,013,339	Jan 07 04:05 PM
Schultes Birgit C	EVP, Chief Scientific Officer	Jan 05 '26	Sale	9.21	8,508	78,359	98,533	Jan 07 04:05 PM
BASTA JAMES	EVP, General Counsel	Jan 05 '26	Sale	9.21	10,397	95,756	101,528	Jan 07 04:05 PM
Cohen Fred E	Director	Jan 05 '26	Buy	9.35	150,000	1,402,500	207,453	Jan 07 04:05 PM
Lebwohl David	EVP, Chief Medical Officer	Jan 05 '26	Sale	9.21	11,903	109,627	121,249	Jan 07 04:04 PM
Clark Eliana	EVP, Chief Technical Officer	Jan 05 '26	Sale	9.21	9,515	87,633	87,118	Jan 07 04:03 PM
Dulac Edward J III	EVP, Chief Financial Officer	Jan 05 '26	Sale	9.21	6,379	58,751	99,683	Jan 07 04:02 PM
Dube Michael P	VP, Chief Accounting Officer	Jan 05 '26	Sale	9.21	2,989	27,529	52,277	Jan 07 04:01 PM
LEONARD JOHN M	President and CEO	Dec 11 '25	Option Exercise	6.83	49,959	341,220	1,127,074	Dec 12 04:09 PM
LEONARD JOHN M	President and CEO	Dec 12 '25	Option Exercise	6.83	8,557	58,444	1,047,485	Dec 12 04:09 PM
LEONARD JOHN M	President and CEO	Dec 11 '25	Sale	9.49	88,146	836,384	1,038,928	Dec 12 04:09 PM
LEONARD JOHN M	Officer	Dec 11 '25	Proposed Sale	9.33	88,146	822,402		Dec 11 04:11 PM

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

PresidentDr. John M. Leonard M.D.

Executive VPMr. Edward J. Dulac III

Executive VP & Chief Scientific OfficerDr. Birgit Schultes Ph.D.

J.D.Mr. James E. Basta Esq.

Co-FounderDr. Rachel E. Haurwitz Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NTLA

Intellia Therapeutics Inc

Upgrade your Finviz experience